新的药物治疗在阿尔茨海默病和帕金森病中显示出神经保护作用。
New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases.
作者信息
Hölscher Christian
机构信息
Neuroscience research group, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK.
出版信息
Neural Regen Res. 2014 Nov 1;9(21):1870-3. doi: 10.4103/1673-5374.145342.
Abstract
Type 2 diabetes is a risk factor for Alzheimer's disease and Parkinson's disease. Insulin signaling in the brains of people with Alzheimer's disease or Parkinson's disease is impaired. Preclinical studies of growth factors showed impressive neuroprotective effects. In animal models of Alzheimer's disease and Parkinson's disease, insulin, glia-derived neurotrophic factor, or analogues of the incretin glucagon-like peptide-1 prevented neurodegenerative processes and improved neuronal and synaptic functionality in Alzheimer's disease and Parkinson's disease. On the basis of these promising findings, several clinical trials are ongoing with the first encouraging clinical results published. This gives hope for developing effective treatments for Alzheimer's disease and Parkinson's disease that are currently unavailable.
摘要
2型糖尿病是阿尔茨海默病和帕金森病的一个风险因素。阿尔茨海默病或帕金森病患者大脑中的胰岛素信号传导受损。生长因子的临床前研究显示出显著的神经保护作用。在阿尔茨海默病和帕金森病的动物模型中，胰岛素、胶质细胞源性神经营养因子或肠促胰岛素胰高血糖素样肽-1的类似物可预防神经退行性过程，并改善阿尔茨海默病和帕金森病中的神经元及突触功能。基于这些有前景的发现，目前正在进行多项临床试验，并且已经公布了首批令人鼓舞的临床结果。这为开发目前尚无的针对阿尔茨海默病和帕金森病的有效治疗方法带来了希望。
相似文献
1
New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases.新的药物治疗在阿尔茨海默病和帕金森病中显示出神经保护作用。
Neural Regen Res. 2014 Nov 1;9(21):1870-3. doi: 10.4103/1673-5374.145342.
2
Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.用于治疗糖尿病的药物在阿尔茨海默病和帕金森病中显示出保护作用。
Sheng Li Xue Bao. 2014 Oct 25;66(5):497-510.
3
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.胰岛素、肠促胰岛素及其他生长因子作为阿尔茨海默病和帕金森病潜在的新型治疗手段。
Biochem Soc Trans. 2014 Apr;42(2):593-9. doi: 10.1042/BST20140016.
4
GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.GIP 在阿尔茨海默病和帕金森病模型中具有神经保护作用。
Peptides. 2020 Mar;125:170184. doi: 10.1016/j.peptides.2019.170184. Epub 2019 Nov 6.
5
Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.新型双重 GLP-1/GIP 受体激动剂在阿尔茨海默病和帕金森病模型中显示出神经保护作用。
Neuropharmacology. 2018 Jul 1;136(Pt B):251-259. doi: 10.1016/j.neuropharm.2018.01.040. Epub 2018 Jan 31.
6
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.GLP-1 的中枢作用：治疗神经退行性疾病的新机遇。
J Endocrinol. 2014 Mar 7;221(1):T31-41. doi: 10.1530/JOE-13-0221. Print 2014 Apr.
7
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.代谢与神经退行性疾病的病理生理学共性证据。
Int Rev Neurobiol. 2020;155:65-89. doi: 10.1016/bs.irn.2020.01.007. Epub 2020 Aug 11.
8
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.胰高血糖素样肽1在阿尔茨海默病和帕金森病中的神经保护作用：深入综述
Front Neurosci. 2022 Sep 1;16:970925. doi: 10.3389/fnins.2022.970925. eCollection 2022.
9
New therapeutic strategy for Parkinson's and Alzheimer's disease.帕金森病和阿尔茨海默病的新治疗策略。
Curr Med Chem. 2010;17(25):2764-74. doi: 10.2174/092986710791859324.
10
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.胰高血糖素样肽-1（GLP-1）类似物在阿尔茨海默病和帕金森病中的神经保护作用。
CNS Drugs. 2019 Mar;33(3):209-223. doi: 10.1007/s40263-018-0593-6.
引用本文的文献
1
Alzheimer's Disease and Inflammaging.阿尔茨海默病与炎症衰老
Brain Sci. 2022 Sep 13;12(9):1237. doi: 10.3390/brainsci12091237.
2
The Interplay between Diabetes and Alzheimer's Disease-In the Hunt for Biomarkers.糖尿病与阿尔茨海默病的相互作用——寻找生物标志物。
Int J Mol Sci. 2020 Apr 15;21(8):2744. doi: 10.3390/ijms21082744.
3
Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.MPTP 帕金森病小鼠模型中 Nrf2 和氮能介导的胃肠道运动障碍。
Dig Dis Sci. 2019 Dec;64(12):3502-3517. doi: 10.1007/s10620-019-05693-5. Epub 2019 Jun 11.
4
Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications.2 型糖尿病与阿尔茨海默病：胰岛素信号的作用及治疗意义。
Int J Mol Sci. 2018 Oct 24;19(11):3306. doi: 10.3390/ijms19113306.
5
Biomaterials for the Treatment of Alzheimer's Disease.用于治疗阿尔茨海默病的生物材料。
Front Bioeng Biotechnol. 2016 Jun 16;4:49. doi: 10.3389/fbioe.2016.00049. eCollection 2016.
6
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.在阿尔茨海默病中，使用胰高血糖素样肽-1类似物进行6个月治疗可预防脑葡萄糖代谢下降：随机、安慰剂对照、双盲临床试验。
Front Aging Neurosci. 2016 May 24;8:108. doi: 10.3389/fnagi.2016.00108. eCollection 2016.
7
A novel method for evaluating brain function and microstructural changes in Parkinson's disease.一种评估帕金森病脑功能和微观结构变化的新方法。
Neural Regen Res. 2015 Dec;10(12):2025-32. doi: 10.4103/1673-5374.172322.
8
Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage.牙源性间充质干细胞——它们在脑损伤和肠道损伤中的抗炎及再生作用潜力
Curr Neuropharmacol. 2016;14(8):914-934. doi: 10.2174/1570159x14666160121115210.
9
The Human Disease-Associated Aβ Amyloid Core Sequence Forms Functional Amyloids in a Fungal Adhesin.与人类疾病相关的Aβ淀粉样蛋白核心序列在真菌粘附素中形成功能性淀粉样蛋白。
mBio. 2016 Jan 12;7(1):e01815-15. doi: 10.1128/mBio.01815-15.
10
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders.用于治疗糖尿病及相关疾病的肠促胰岛素肽开发新视角。
World J Diabetes. 2015 Nov 10;6(15):1285-95. doi: 10.4239/wjd.v6.i15.1285.
本文引用的文献
1
A critical analysis of the 'amyloid cascade hypothesis'.对“淀粉样蛋白级联假说”的批判性分析。
Folia Neuropathol. 2014;52(3):211-25.
2
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.Fc 受体在神经退行性变中的新作用——对阿尔茨海默病免疫治疗的影响。
Front Neurosci. 2014 Aug 21;8:235. doi: 10.3389/fnins.2014.00235. eCollection 2014.
3
Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.帕金森病大鼠模型中经鼻给予胶质细胞源性神经营养因子的神经营养和神经保护作用
Neuroscience. 2014 Aug 22;274:11-23. doi: 10.1016/j.neuroscience.2014.05.019. Epub 2014 May 17.
4
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.在帕金森病中，艾塞那肽治疗12个月后运动和认知优势依然存在。
J Parkinsons Dis. 2014;4(3):337-44. doi: 10.3233/JPD-140364.
5
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.胰岛素、肠促胰岛素及其他生长因子作为阿尔茨海默病和帕金森病潜在的新型治疗手段。
Biochem Soc Trans. 2014 Apr;42(2):593-9. doi: 10.1042/BST20140016.
6
Insulin resistance, neuroinflammation, and Alzheimer's disease.胰岛素抵抗、神经炎症与阿尔茨海默病。
Rev Neurosci. 2014;25(4):509-25. doi: 10.1515/revneuro-2013-0050.
7
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.肠促胰岛素激素胰高血糖素样肽 1 和葡萄糖依赖性胰岛素促分泌多肽在阿尔茨海默病的小鼠模型中具有神经保护作用。
Alzheimers Dement. 2014 Feb;10(1 Suppl):S47-54. doi: 10.1016/j.jalz.2013.12.009.
8
Protective effect of leptin and ghrelin against toxicity induced by amyloid-β oligomers in a hypothalamic cell line.瘦素和胃饥饿素对淀粉样β寡聚体诱导的下丘脑细胞系毒性的保护作用。
J Neuroendocrinol. 2014 Mar;26(3):176-85. doi: 10.1111/jne.12138.
9
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.TNF-α 通过 PKR 介导阿尔茨海默病β-淀粉样寡聚体诱导的小鼠和猴子的记忆损伤和脑 IRS-1 抑制。
Cell Metab. 2013 Dec 3;18(6):831-43. doi: 10.1016/j.cmet.2013.11.002.
10
Gut hormones as therapeutic agents in treatment of diabetes and obesity.肠激素作为治疗糖尿病和肥胖症的治疗药物。
Curr Opin Pharmacol. 2013 Dec;13(6):996-1001. doi: 10.1016/j.coph.2013.09.005. Epub 2013 Sep 20.
Zotero 插件